Cardiff Oncology Resolves NMS Dispute, Expands Onvansertib Rights — Cardiff Oncology, Inc.

Event summary

Cardiff Oncology and Nerviano Medical Sciences (NMS) amended their 2017 exclusive license agreement for onvansertib, resolving all outstanding disputes.
The settlement includes a mutual release of all claims and a joint request to dismiss pending litigation in the U.S. District Court for the Southern District of California.
The amended agreement clarifies and expands the royalty structure and includes development objectives for Cardiff’s upcoming Phase 3 program for onvansertib.
NMS gains rights to appoint a Board observer and join Cardiff’s Scientific Advisory Board.
Onvansertib, a PLK1 inhibitor, is advancing toward a registrational trial in first-line RAS-mutated metastatic colorectal cancer (mCRC).

The big picture

The resolution of the dispute between Cardiff Oncology and NMS strengthens Cardiff’s control over onvansertib, a promising treatment for RAS-mutated mCRC. This agreement reflects a broader trend in biotech partnerships, where collaborative frameworks are increasingly used to mitigate litigation risks and accelerate clinical development. The expanded royalty structure and governance rights for NMS suggest a strategic realignment aimed at optimizing the drug’s path to market.

What we're watching

Clinical Development: The pace at which Cardiff Oncology advances onvansertib into a global Phase 3 study for first-line RAS-mutated mCRC will determine its commercial viability.
Governance Dynamics: NMS’s appointment of a Board observer and participation in Cardiff’s Scientific Advisory Board could influence strategic decisions and operational alignment.
Execution Risk: Whether Cardiff can sustain the expanded collaborative framework with NMS while maintaining its lead in PLK1 inhibition will be critical for long-term success.